Sorbent Therapeutics is a private biopharmaceutical company developing therapies for patients requiring targeted cation and fluid removal from the body. The company is focused on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. Sorbent is headquartered in Sunnyvale, California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/15/14 | $6,500,000 | Series D |
AgeChem Venture Fund ARCH Venture Partners CMEA Capital Novartis Venture Funds Sofinnova Ventures | undisclosed |
